• CStone Pharmaceuticals posted revenue of RMB 205.1 million, more than doubled year over year, driven by higher pharmaceutical product sales.
• Loss for the period narrowed to RMB 252.3 million; basic loss per share improved to RMB 0.17.
• Gross profit swung to RMB 94.2 million as cost of revenue fell to RMB 110.9 million.
• Research and development expenses climbed to RMB 205.5 million; selling and marketing expenses rose to RMB 73.1 million.
• Cash, cash equivalents and time deposits totaled RMB 1.56 billion; CS2009 Phase III MRCTs remain planned for end-2026 initiation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260827-12302811), on August 27, 2026, and is solely responsible for the information contained therein.